Fig. 1. Characterization of these Cap-3M2e proteins.

(a) Primary pattern structure of six recombinant Cap-3M2e. (b) M2e sequence of the human, swine and avian IAV which were used in challenging experiment. (c) Schematic illustration of Cap-3M2e VLPs nanovaccine. The VLPs model was derived from the PDB database (3R0R). (d) SDS-PAGE analysis of these purified Cap-3M2e proteins. Lane M: molecular weight markers; lane 1: Cap; lane 2: Cap-hsaM2e; lane 3: Cap-hasM2e; lane 4: Cap-shaM2e; lane 5: Cap-sahM2e; lane 6: Cap-ahsM2e; lane 7: Cap-ashM2e. (e) Western blot analysis of these purified Cap-3M2e protein. The upper figure shows the reactivity of the recombinant protein with PCV2 positive sera. The lower figure shows the reactivity of recombinant protein with M2e specific monoclonal antibody 14C2. Lane M: molecular weight markers; lane 1: Cap; lane 2: Cap-hsaM2e; lane 3: Cap-hasM2e; lane 4: Cap-shaM2e; lane 5: Cap-sahM2e; lane 6: Cap-ahsM2e; lane 7: Cap-ashM2e.